Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (ALVO) is a pioneering biotech company specializing in biosimilar medicines, offering patients worldwide access to high-quality alternatives to biologic therapies. This page aggregates official announcements, financial updates, and strategic developments critical for understanding the company's market position.
Access real-time updates on regulatory milestones, manufacturing expansions, and partnership agreements that drive Alvotech's mission to deliver cost-effective therapies. Users will find earnings reports, pipeline progress, and market authorization news across therapeutic areas including immunology and oncology.
Key updates include biosimilar candidate developments, quality compliance achievements, and global distribution agreements. Bookmark this page for streamlined tracking of Alvotech's operational advancements and industry contributions.
Rhea-AI Summary
Alvotech (NASDAQ: ALVO), in partnership with Kashiv Biosciences and Advanz Pharma, announced positive topline results from their confirmatory efficacy study for AVT23, a proposed biosimilar to Xolair® (omalizumab). The study met its primary endpoint, demonstrating therapeutic equivalence and comparable safety to Xolair® in patients with Chronic Spontaneous Urticaria (CSU).
The double-blind study enrolled 600 patients, with 400 receiving the confirmatory dose of 300mg. The primary efficacy measure focused on changes in weekly Itch Severity Score at Week 12. The UK MHRA has already validated the marketing authorization application, with an EMA filing expected by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) and Advanz Pharma announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for AVT06, their proposed biosimilar to Eylea (aflibercept 2 mg). The biosimilar is intended to treat various eye disorders including wet age-related macular degeneration, visual impairment due to macular oedema, diabetic macular oedema, and myopic choroidal neovascularisation. Alvotech will handle development and commercial supply, while Advanz Pharma will manage registration and exclusive commercialization in most European countries. Notably, Eylea's global sales reached approximately $9 billion in 2024, with one-third coming from Europe. A confirmatory clinical study completed in January 2024 demonstrated therapeutic equivalence between AVT06 and Eylea. Additionally, Alvotech is developing AVT29, a proposed biosimilar to the higher-dose Eylea HD (aflibercept 8 mg).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) has successfully completed a private placement of shares and Swedish Depositary Receipts (SDRs) announced on June 4, 2025. The placement attracted approximately 40 institutional investors, with 60% of demand coming from Sweden, Norway, and UK investors, and 30% from US-based funds. Notably, over 80% of the allocated shares and SDRs were purchased by new investors. The placement involved the transfer of 7.5 million treasury shares from Alvotech's subsidiary Alvotech Manco ehf. According to CEO Róbert Wessman, this placement will diversify and strengthen Alvotech's shareholder base while increasing the free float of SDRs on Nasdaq Stockholm, where approximately 8.5 million SDRs are currently trading.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
News
Rhea-AI Summary
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami from June 9-11, 2025. The company's management team will conduct one-on-one meetings during the event. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on June 11 at 8:00 am EDT. The session will be webcast live and accessible to the public through Alvotech's investor relations website, with a replay available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami from June 9-11, 2025. The company's management team will conduct one-on-one meetings during the event. Chief Strategy Officer Dr. Balaji Prasad will participate in a fireside chat on June 11, 2025, at 8:00 am EDT. The session will be publicly accessible via webcast through Alvotech's investor relations website, with a replay available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) and Dr. Reddy's Laboratories have announced a strategic collaboration to co-develop, manufacture, and commercialize a biosimilar version of Keytruda (pembrolizumab), a major cancer treatment drug. The partnership leverages both companies' biosimilar expertise to accelerate development and expand global reach. Under the agreement, both parties will share development costs, manufacturing responsibilities, and commercialization rights globally. This collaboration targets a significant market opportunity, as Keytruda generated US$29.5 billion in worldwide sales in 2024. The partnership aims to increase the availability of cost-effective biologic medications for cancer treatment worldwide, with oncology being a key focus area for both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) has successfully completed a private placement of 7.5 million shares, comprising 5,833,500 SDRs and 1,666,500 ordinary shares, priced at SEK 100.00 per SDR and ISK 1320.83 per ordinary share. The placement raised SEK 750 million in gross proceeds, with strong interest primarily from Swedish and international investors outside Iceland. The funds will be used to scale up R&D efforts, particularly in Sweden following the Xbrane R&D operations acquisition, capitalize on growth opportunities, and for general corporate purposes. Settlement is expected around June 10, 2025. The company and its executives have agreed to lock-up periods of 180 days, while major shareholders have committed to 90-day lock-up periods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) announces plans to conduct a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares, targeting Swedish and international institutional investors through an accelerated bookbuilding process. The offering will utilize existing treasury shares, with DNB Carnegie, Citi, SEB, and ACRO serving as Joint Bookrunners. The placement aims to strengthen Alvotech's shareholder base, particularly in Sweden following its recent Nasdaq Stockholm listing. Proceeds will fund R&D activities expansion, especially in Sweden after acquiring Xbrane's R&D operations. The company and insiders have agreed to lock-up periods ranging from 90-180 days post-settlement. Major shareholders Aztiq Pharma, Alvogen Lux, and Celtic Holdings II are maintaining their positions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) has completed its acquisition of Xbrane Biopharma AB's R&D organization in Sweden and its biosimilar candidate to Cimzia® (certolizumab pegol). The transaction, valued at approximately SEK 275 million (US$28.9 million), includes a cash payment of SEK 102.2 million, convertible debt assumption of SEK 152.75 million, and accounts payable assumption of SEK 20 million related to the biosimilar candidate. The acquisition, which received approval from Xbrane's Extraordinary General Meeting on April 14, 2025, aims to expand Alvotech's development capabilities and establish a strong presence in the Swedish life science sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
Rhea-AI Summary
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025 in New York. The event will take place from June 3-5, 2025, where the company's management team will conduct one-on-one meetings. Dr. Balaji Prasad, Chief Strategy Officer, will deliver a business update presentation on June 5, 2025, from 10:30-11:00 am EDT. The presentation will be accessible via live video webcast on Alvotech's investor relations website, with a replay available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
FAQ
What is the current stock price of Alvotech (ALVO)?
The current stock price of Alvotech (ALVO) is $9.22 as of June 24, 2025.
What is the market cap of Alvotech (ALVO)?
The market cap of Alvotech (ALVO) is approximately 2.9B.
Alvotech
Nasdaq:ALVO
ALVO Rankings
ALVO Stock Data
2.85B
72.97M
64.88%
6.26%
0.17%
Drug Manufacturers - Specialty & Generic
Healthcare
Luxembourg
Luxembourg